Analysts Offer Predictions for MDGL Q3 Earnings

Key Points

• HC Wainwright predicts Madrigal Pharmaceuticals will report a Q3 2025 EPS of ($1.14), with a full-year estimate at ($23.47) per share and has a "Buy" rating with a target price of $500.00.
• The company recently reported quarterly earnings of ($1.90) per share, significantly beating analysts' expectations, with revenue up 1357.5% year-over-year.
• Institutional investors hold 98.50% of Madrigal's stock, indicating strong interest from large financial entities, while recent insider selling occurred from key executives.

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) - Equities researchers at HC Wainwright issued their Q3 2025 EPS estimates for Madrigal Pharmaceuticals in a report issued on Thursday, September 4th. HC Wainwright analyst A. Fein anticipates that the biopharmaceutical company will post earnings per share of ($1.14) for the quarter. HC Wainwright has a "Buy" rating and a $500.00 price target on the stock. The consensus estimate for Madrigal Pharmaceuticals' current full-year earnings is ($23.47) per share. HC Wainwright also issued estimates for Madrigal Pharmaceuticals' Q4 2025 earnings at ($0.46) EPS, FY2025 earnings at ($6.79) EPS, Q1 2026 earnings at ($1.40) EPS, Q2 2026 earnings at ($1.44) EPS, Q3 2026 earnings at ($1.45) EPS, Q4 2026 earnings at ($1.48) EPS, FY2026 earnings at ($5.77) EPS, FY2027 earnings at ($4.25) EPS, FY2028 earnings at $34.48 EPS and FY2029 earnings at $69.75 EPS.

Madrigal Pharmaceuticals (NASDAQ:MDGL - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported ($1.90) earnings per share for the quarter, topping analysts' consensus estimates of ($3.48) by $1.58. The company had revenue of $212.80 million for the quarter, compared to analyst estimates of $158.94 million. Madrigal Pharmaceuticals had a negative return on equity of 38.38% and a negative net margin of 54.68%.The business's revenue for the quarter was up 1357.5% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($7.10) EPS.

A number of other research analysts also recently commented on MDGL. TD Cowen upped their price objective on shares of Madrigal Pharmaceuticals from $390.00 to $554.00 and gave the company a "buy" rating in a research note on Tuesday, August 26th. UBS Group restated a "buy" rating and issued a $523.00 target price (up from $458.00) on shares of Madrigal Pharmaceuticals in a report on Tuesday, August 12th. Cowen reaffirmed a "buy" rating on shares of Madrigal Pharmaceuticals in a research note on Tuesday, August 26th. Canaccord Genuity Group lifted their price target on shares of Madrigal Pharmaceuticals from $420.00 to $428.00 and gave the company a "buy" rating in a report on Wednesday, August 6th. Finally, JMP Securities upped their price objective on Madrigal Pharmaceuticals from $483.00 to $485.00 and gave the stock a "market outperform" rating in a report on Wednesday, August 20th. Nine investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $471.13.

Madrigal Pharmaceuticals Trading Down 4.1%

Madrigal Pharmaceuticals stock traded down $18.62 during trading on Monday, hitting $430.11. The company's stock had a trading volume of 280,508 shares, compared to its average volume of 380,801. The stock's fifty day moving average is $356.02 and its 200 day moving average is $324.53. Madrigal Pharmaceuticals has a 1-year low of $200.63 and a 1-year high of $457.16. The stock has a market capitalization of $9.55 billion, a price-to-earnings ratio of -33.47 and a beta of -1.02. The company has a debt-to-equity ratio of 0.17, a quick ratio of 4.78 and a current ratio of 5.11.

Insider Buying and Selling

In other news, CEO William John Sibold sold 7,279 shares of the stock in a transaction dated Tuesday, September 9th. The stock was sold at an average price of $445.63, for a total value of $3,243,740.77. Following the completion of the sale, the chief executive officer owned 102,474 shares in the company, valued at approximately $45,665,488.62. This trade represents a 6.63% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Kenneth Bate sold 10,000 shares of the business's stock in a transaction that occurred on Friday, August 15th. The stock was sold at an average price of $365.20, for a total value of $3,652,000.00. Following the transaction, the director directly owned 2,627 shares in the company, valued at $959,380.40. This trade represents a 79.20% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have bought 165,683 shares of company stock valued at $61,921,142 and have sold 309,019 shares valued at $112,705,072. 21.50% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Madrigal Pharmaceuticals

Large investors have recently added to or reduced their stakes in the company. VSM Wealth Advisory LLC purchased a new stake in Madrigal Pharmaceuticals during the 1st quarter worth $25,000. Accent Capital Management LLC purchased a new stake in shares of Madrigal Pharmaceuticals during the first quarter worth about $25,000. AlphaQuest LLC increased its position in shares of Madrigal Pharmaceuticals by 412.5% during the second quarter. AlphaQuest LLC now owns 82 shares of the biopharmaceutical company's stock worth $25,000 after acquiring an additional 66 shares during the last quarter. Summit Securities Group LLC acquired a new position in shares of Madrigal Pharmaceuticals in the first quarter worth about $33,000. Finally, Farther Finance Advisors LLC boosted its holdings in Madrigal Pharmaceuticals by 825.0% in the first quarter. Farther Finance Advisors LLC now owns 111 shares of the biopharmaceutical company's stock valued at $36,000 after purchasing an additional 99 shares during the last quarter. 98.50% of the stock is owned by institutional investors and hedge funds.

Madrigal Pharmaceuticals Company Profile

Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.